NGL Fine Chem Ltd

NGL Fine Chem Ltd

₹ 2,053 1.91%
04 Mar 4:01 p.m.
About

Established in 1981, NGL Fine-Chem Limited manufacturers and markets APIs, Intermediates and Finished Dosage forms for human and animal pharmaceutical product. It caters to various Indian and global companies with high quality and reliable products. [1]

Key Points

Product Portfolio Q2FY24
Presently, Veterinary APIs are the main product of the company which account for 83% of its revenues, followed by Veterinary Formulations (6%), Human APIs (6%), and others (5%).[1] The company has 26 APIs (24 Veterinary APIs, 2 Human APIs), 4 Intermediates and 10 finished dosage forms.[2]

  • Market Cap 1,258 Cr.
  • Current Price 2,053
  • High / Low 2,440 / 1,161
  • Stock P/E 34.7
  • Book Value 393
  • Dividend Yield 0.09 %
  • ROCE 11.5 %
  • ROE 9.31 %
  • Face Value 5.00

Pros

Cons

  • Debtor days have increased from 71.3 to 86.5 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
72.79 71.79 75.91 78.50 81.37 78.21 63.58 64.95 69.80 74.17 69.11 79.44 84.81
50.98 50.96 52.78 61.96 69.32 68.22 63.47 60.20 62.37 62.30 61.51 66.31 73.86
Operating Profit 21.81 20.83 23.13 16.54 12.05 9.99 0.11 4.75 7.43 11.87 7.60 13.13 10.95
OPM % 29.96% 29.02% 30.47% 21.07% 14.81% 12.77% 0.17% 7.31% 10.64% 16.00% 11.00% 16.53% 12.91%
3.65 2.53 4.92 4.89 4.41 2.28 3.01 4.10 2.95 1.45 3.80 3.76 4.19
Interest 0.37 0.33 0.37 0.40 0.42 0.37 0.50 0.12 0.26 0.32 0.24 0.36 0.28
Depreciation 1.86 1.85 1.93 1.96 1.90 1.88 1.96 2.02 2.00 1.92 2.00 2.02 2.07
Profit before tax 23.23 21.18 25.75 19.07 14.14 10.02 0.66 6.71 8.12 11.08 9.16 14.51 12.79
Tax % 24.62% 32.44% 24.85% 25.64% 23.20% 21.56% 24.24% 26.08% 25.00% 23.01% 14.74% 24.47% 30.41%
17.51 14.31 19.35 14.19 10.85 7.86 0.51 4.96 6.09 8.53 7.81 10.97 8.90
EPS in Rs 28.34 23.16 31.32 22.97 17.56 12.72 0.83 8.03 9.86 13.81 12.64 17.76 14.41
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
36 56 79 88 96 100 114 153 152 258 319 275 308
32 48 68 73 74 74 92 121 129 181 253 246 264
Operating Profit 4 8 11 15 22 25 22 32 23 77 66 29 44
OPM % 11% 14% 14% 17% 23% 26% 19% 21% 15% 30% 21% 10% 14%
0 0 -1 2 0 1 3 4 1 9 13 8 13
Interest 1 1 2 2 2 1 2 3 3 2 2 2 1
Depreciation 1 2 2 3 3 3 5 6 7 7 8 8 8
Profit before tax 2 4 7 13 18 23 18 28 14 76 69 27 48
Tax % 32% 35% 32% 35% 36% 35% 29% 27% 26% 27% 24% 24%
1 3 5 8 11 15 13 20 11 55 52 20 36
EPS in Rs 1.70 4.71 7.33 13.48 18.45 24.10 20.38 32.58 17.16 89.79 84.57 32.57 58.62
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 5% 10% 2% 2% 5%
Compounded Sales Growth
10 Years: 17%
5 Years: 19%
3 Years: 22%
TTM: 11%
Compounded Profit Growth
10 Years: 21%
5 Years: 10%
3 Years: 19%
TTM: 86%
Stock Price CAGR
10 Years: 55%
5 Years: 35%
3 Years: 11%
1 Year: 49%
Return on Equity
10 Years: 23%
5 Years: 23%
3 Years: 24%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 3 3 3 3 3 3 3 3 3 3 3 3 3
Reserves 14 17 21 30 41 56 69 89 98 152 203 222 240
10 13 17 13 14 23 27 27 28 16 30 32 27
10 14 15 21 19 20 31 23 26 34 41 30 52
Total Liabilities 37 47 56 67 78 102 129 142 156 206 278 288 322
10 18 19 17 24 25 56 61 61 58 59 59 58
CWIP 5 0 0 1 2 16 3 0 0 1 6 26 33
Investments 2 0 0 2 3 6 6 9 14 33 32 43 51
21 30 37 46 49 55 63 73 80 115 180 159 180
Total Assets 37 47 56 67 78 102 129 142 156 206 278 288 322

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
1 -0 -0 8 8 10 22 9 20 27 13 32
-4 -3 -4 -3 -10 -10 -21 -10 -19 -24 -13 -24
3 4 3 -4 2 0 0 0 -1 -1 -1 -1
Net Cash Flow -0 1 -1 1 0 -0 1 -1 -0 2 -1 7

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 115 100 110 107 123 110 89 79 63 53 74 86
Inventory Days 113 126 77 106 90 114 134 106 154 132 133 69
Days Payable 156 148 105 150 122 139 187 92 114 94 84 59
Cash Conversion Cycle 72 78 82 63 91 85 35 93 103 91 124 97
Working Capital Days 81 88 88 77 96 85 54 107 98 78 116 104
ROCE % 11% 19% 24% 29% 37% 34% 22% 28% 15% 52% 35% 12%

Shareholding Pattern

Numbers in percentages

2 Recently
Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
73.81% 73.81% 73.81% 73.81% 73.81% 73.81% 73.81% 73.81% 73.53% 73.53% 73.06% 73.06%
0.00% 0.00% 0.00% 0.00% 0.01% 0.05% 0.05% 0.00% 0.00% 0.00% 0.02% 0.04%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00%
26.19% 26.19% 26.19% 26.19% 26.18% 26.14% 26.13% 26.19% 26.47% 26.46% 26.93% 26.91%
No. of Shareholders 5,4567,14610,83215,69517,06818,04218,50418,44018,28717,06617,62316,410

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls